Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Sells $406,486.95 in Stock

Key Points

• Agios Pharmaceuticals CEO Brian Goff sold 11,085 shares at an average price of $36.67, totaling approximately $406,487, resulting in an 8.23% decrease in his ownership.
• The company's recent earnings report showed a miss in earnings per share of ($1.93), compared to the consensus estimate of ($1.74), with revenue of $12.50 million.
• Escalating interest from hedge funds has seen Erste Asset Management increase its stake in Agios Pharmaceuticals by 10.9%, adding 220,000 shares during the last quarter.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 11,085 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares of the company's stock, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Brian Goff also recently made the following trade(s):

• On Tuesday, June 24th, Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $33.54, for a total value of $627,198.00.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.33 during mid-day trading on Friday, hitting $37.01. The stock had a trading volume of 362,261 shares, compared to its average volume of 987,132. The firm has a market cap of $2.15 billion, a P/E ratio of 3.36 and a beta of 0.80. The business has a 50 day moving average price of $36.50 and a two-hundred day moving average price of $32.76. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on AGIO shares. Bank of America lowered their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Scotiabank lowered their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at $49,290,000. TCG Crossover Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $23,182,000. SCS Capital Management LLC acquired a new position in Agios Pharmaceuticals during the first quarter worth $17,905,000. Adage Capital Partners GP L.L.C. increased its position in Agios Pharmaceuticals by 145.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock worth $21,770,000 after buying an additional 440,000 shares in the last quarter. Finally, Palo Alto Investors LP purchased a new stake in shares of Agios Pharmaceuticals in the first quarter valued at $8,104,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.